Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tong Ren Tang Technologies Co ( (HK:1666) ) just unveiled an announcement.
Tong Ren Tang Technologies has convened its 2025 annual general meeting for 12 June 2026 in Beijing, where shareholders will review the audited 2025 financial statements and the board’s annual report. The company will also seek approval for a final dividend of RMB0.18 per share, signalling confidence in its earnings and providing a cash return to investors.
Shareholders will vote on reappointing Ernst & Young and Ernst & Young Hua Ming LLP as overseas and domestic auditors for 2026, as well as amendments to meeting rules and the articles of association. The board is further asking for a general mandate to issue up to 20% additional shares, which would give management flexibility to raise capital and adjust the company’s capital structure as needed.
More about Tong Ren Tang Technologies Co
Tong Ren Tang Technologies Co. Ltd. is a Mainland China-based pharmaceutical company specialising in traditional Chinese medicine products. Listed in Hong Kong, it focuses on manufacturing and distributing herbal remedies and health supplements, serving both domestic and international markets through retail and wholesale channels.
YTD Price Performance: -11.11%
Average Trading Volume: 1,000,911
Technical Sentiment Signal: Sell
Current Market Cap: HK$5.02B
See more data about 1666 stock on TipRanks’ Stock Analysis page.